Roche Holding AG (SWX:RO)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 293.65B +28.0% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | n/a |
| PE Ratio | 22.80 |
| Forward PE | 18.03 |
| Dividend | 9.80 (2.64%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 15,835 |
| Average Volume | 24,123 |
| Open | 375.60 |
| Previous Close | 374.80 |
| Day's Range | 371.00 - 375.60 |
| 52-Week Range | 244.00 - 379.80 |
| Beta | 0.20 |
| RSI | 63.99 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
FDA Approves Genentech's Venclexta And Acalabrutinib Combo For Untreated CLL
(RTTNews) - Genentech, a member of the Roche Holding AG (RHHBY), said on Friday that the U.S. Food and Drug Administration has approved the combination of Venclexta plus acalabrutinib for the treatmen...
FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the com...
FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Basel, 20 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has accepted the company's New Drug Application for girede...
Change to the Roche Enlarged Corporate Executive Committee
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effecti...
Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically sig...
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Basel, 16 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistica...
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MAJESTY study in adults with primary membranous nep...
Roche Holding AG (RHHBY) Shareholder/Analyst Presentation
2026-02-09. The following slide deck was published by Roche Holding AG in conjunction with this event.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Says Experimental Drug Helped Slow Disability In Progressive Multiple Sclerosis Study
Roche Holdings AG (OTC: RHHBY) on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is a...
Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial
Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple sclerosi...
Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in red...
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc...
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Basel, 07 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK) inhibi...
Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the...
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?
Weight loss candidates from Amgen and Roche performed well in phase 2 studies. These could be exciting additions to these companies' drug portfolios.
ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025
ClearBridge International Growth ADR Strategy underperformed its primary MSCI EAFE benchmark for the fourth quarter of 2025, and slightly underperformed its secondary MSCI EAFE Growth benchmark.
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG 2025 Q4 - Results - Earnings Call Presentation
2026-01-29. The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q4 earnings call.
Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic ...
Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic Investments Drive Profit Surge
Full Year 2025 Roche Holding AG Earnings Call Transcript
Full Year 2025 Roche Holding AG Earnings Call Transcript
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular...